The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering.World revenue for the Antibody Drug Conjugates Market is set to surpass US$16 billion in 2025 ...

Dublin, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Report 2025-2035" has been added to ResearchAndMarkets.com's offering. World revenue for the Antibody Drug Conjugates ...

British drug maker AstraZeneca Plc (AZN.L, AZN) and Daiichi Sankyo (DSKYF.PK) announced Monday that their Datroway (datopotamab ...

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...

Celltrion targets innovative drug development with new ADC and antibody candidates Celltrion aims for growth by venturing ...

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...

From groundbreaking immunotherapies to advanced targeted treatments, oncology is set to make historic strides in the year ...

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...

Transforming the landscape of drug discovery with next-gen capabilities in obesity research, small molecule and antibody design, antibody-drug conjugate development, and interactive AI AlpaMeld Logo ...

“We are delighted to announce that Radiance Biopharma was chosen to present at Biotech Showcase 2025 in San Francisco,” said Robert Brooks, JD, Chief Executive Officer, of Radiance. “We are eager to ...

Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug development ...